Antiva raises $16 million in Series B financing to advance antiviral substance through Stage 1 clinical trials Antiva Biosciences, Inc. , a biopharmaceutical organization developing antiviral therapeutics, today announced that it offers raised $16 million in a Series B financing, its initial institutional round malegra pro active read more . In addition, the business announced that Gail Maderis has been appointed president and chief executive officer. The funding was co-led by Canaan Companions and Sofinnova Ventures, with existing investors contributing to the financing also. Proceeds from the funding will be utilized to advance Antiva's lead compound, ABI-1968, through Phase 1 clinical trials. ABI-1968 is usually a topical antiviral for the treatment of high-risk strains of individual papillomavirus infections, the root cause of cervical tumor.

malegra for sale

Several studies possess indicated that prescriptions for these medications have been raising among adolescents and kids, raising concerns among professionals and the public. However, no national data possess previously been available, according to background info in this article. Most prescriptions directed at children and adolescents are for second-generation antipsychotics, which are not authorized by the U.S. Drug and Meals Administration for pediatric individuals. Tag Olfson, M.D., M.P.H., College of Physicians and Surgeons, Columbia University, NY, and colleagues analyzed data from a nationwide survey of office-based physicians executed yearly by federal researchers.